Cancer Immunotherapies designed to generate a cell-mediated immune response against tumors are emerging as frontline treatment options for cancer; however, concerns regarding efficacy, safety and cost efficacy have limited the use of these treatments. To address these weaknesses, we have developed a novel immunotherapy that utilizes a tumor-targeting peptide capable of delivering previously encountered antigenic peptides specifically to cancer cells and facilitating their presentation through the MHC class I pathway. Our therapy utilizes a modular synthetic nanoparticle delivery system comprising of three components: a neutral stealth liposome, encapsulated synthetic immunogenic HLA class I restricted peptides derived from measles virus (MV), and a tumor-targeting peptide on the external surface of the liposome. The targeting peptide results in accumulation of the liposomes specifically inside cancer cells and facilitates presentation of the MV-derived immunogenic peptides in HLA class I molecules. We refer to this system as TALL (Targeted Antigen Loaded Liposomes). Therefore, TALL can generate a secondary immune response specifically against the targeted tumor cells in a patient who has been previously vaccinated against or infected by MV. In short, we are attempting to trick the immune system into responding as though the cancer cell is infected with MV without the use of a viral particle. The tumor targeting peptide has undergone chemical optimization to improve cell specificity, affinity, solubility and biodistribution. The mechanism of cellular internalization of the liposome mediated by the targeting peptide has been elucidated. We have demonstrated a significant reduction in subcutaneous tumor growth using P-TALL in aggressive LLC1 and 4T1 murine models with no gross toxicity.